Skip to content
2000
image of Juanbi Lijieqing Decoction Inhibits TLR4/NF-κB Signaling Pathway by Promoting PPARγ Expression to Relieve Acute Gouty Arthritis
file format pdf download PDF

Abstract

Introduction

This study aimed to investigate the mechanism of Juanbi Lijieqing Decoction (JLD) in alleviating acute gouty arthritis (AGA) by modulating PPARγ expression to suppress the TLR4/NF-κB pathway.

Methods

A total of 84 male SD rats were divided into 7 groups of 12 rats. One group was randomly selected as the normal control group (Group A), while the remaining 72 rats were used to establish an acute gouty arthritis model through intraperitoneal injection of potassium oxonate combined with MSU ankle joint injection. These rats were randomly assigned to the model group (Group B), the high-dose Juanbi Lijieqing Decoction group (Group C), the medium-dose group (Group D), the low-dose group (Group E), the etoricoxib group (Group F), and the pioglitazone group (Group G), with 12 rats per group. The acute gouty arthritis model was established by intraperitoneal injection of potassium oxonate, followed by monosodium urate (MSU) injection into the ankle joint, and then by pharmacological intervention in each group. The ankle swelling index, pain threshold changes, and serum uric acid levels were observed in each group of rats. The pathological state of synovial tissue in each group was evaluated by hematoxylin-eosin (HE) staining. The levels of TNF-α, IL-6, and IL-1β were detected by enzyme-linked immunosorbent assay (ELISA). The protein expressions of TLR4, NF-κB, and PPARγ were detected and using Western blot.

Results

JLD effectively reduced local swelling, relieved pain, and lowered serum uric acid levels in rats with AGA. Both and experiments demonstrated that the Chinese medicine groups showed a significant reduction in TNF-α, IL-1β, and IL-6 levels. Moreover, in experiments, the expression of PPARγ protein was significantly upregulated in the JLD and pioglitazone groups, whereas the expressions of TLR4 and NF-κB p65 proteins were significantly downregulated, a pattern not observed in the etoricoxib group. experiments demonstrated significant increases in PPARγ protein expression in the pioglitazone and medicated serum groups, accompanied by significant decreases in TLR4 protein expression. Meanwhile, the NF-κB inhibitor group only exhibited a downregulation of TLR4 protein expression.

Discussion

Our findings demonstrated that JLD alleviated acute gouty arthritis by upregulating PPARγ expression, which subsequently inhibited the TLR4/NF-κB signaling pathway. This mechanism effectively reduced inflammatory cytokine production (TNF-α, IL-1β, and IL-6), explaining the observed anti-swelling and analgesic effects.

Conclusion

JLD mitigates AGA symptoms by promoting PPARγ, which in turn inhibits TLR4/NF-κB signaling, thereby reducing inflammation, uric acid, and joint swelling. This highlights the therapeutic potential of JLD for gout management, though long-term effects and molecular targets warrant further study.

2025 © 2025 The Author(s). Published by Bentham Science Publisher.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Loading

Article metrics loading...

/content/journals/cchts/10.2174/0113862073378606250616114958
2025-07-03
2025-09-14

  • From This Site

    /content/journals/cchts/10.2174/0113862073378606250616114958
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cchts/10.2174/0113862073378606250616114958/BMS-CCHTS-2024-809.html?itemId=/content/journals/cchts/10.2174/0113862073378606250616114958&mimeType=html&fmt=ahah

References

  1. Dalbeth N. Gosling A.L. Gaffo A. Abhishek A. Gout. Lancet 2021 397 10287 1843 1855 10.1016/S0140‑6736(21)00569‑9 33798500
    [Google Scholar]
  2. Liu F. Bai Y. Wan Y. Luo S. Zhang L. Wu X. Chen R. Yin Z. Xie Y. Guo P. DaiTongXiao improves gout nephropathy by inhibiting inflammatory response through the TLR4/MyD88/NF-κB pathway. Front. Pharmacol. 2024 15 1447241 10.3389/fphar.2024.1447241 39170709
    [Google Scholar]
  3. Pascart T. Dauphin E. Yokose C. Jauffret C. Pacaud A. Laurent V. Ducoulombier V. Choi H.K. Budzik J.F. The role of renal dual-energy computed tomography in exploring the gouty kidney: The RENODECT study. Ann. Med. 2025 57 1 2458783 10.1080/07853890.2025.2458783 39881533
    [Google Scholar]
  4. FitzGerald J.D. Dalbeth N. Mikuls T. Brignardello-Petersen R. Guyatt G. Abeles A.M. Gelber A.C. Harrold L.R. Khanna D. King C. Levy G. Libbey C. Mount D. Pillinger M.H. Rosenthal A. Singh J.A. Sims J.E. Smith B.J. Wenger N.S. Bae S.S. Danve A. Khanna P.P. Kim S.C. Lenert A. Poon S. Qasim A. Sehra S.T. Sharma T.S.K. Toprover M. Turgunbaev M. Zeng L. Zhang M.A. Turner A.S. Neogi T. 2020 American college of rheumatology guideline for the management of gout. Arthritis Care Res. 2020 72 6 744 760 10.1002/acr.24180 32391934
    [Google Scholar]
  5. Dehlin M. Jacobsson L. Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat. Rev. Rheumatol. 2020 16 7 380 390 10.1038/s41584‑020‑0441‑1 32541923
    [Google Scholar]
  6. Mattiuzzi C. Lippi G. Recent updates on worldwide gout epidemiology. Clin. Rheumatol. 2020 39 4 1061 1063 10.1007/s10067‑019‑04868‑9 31836936
    [Google Scholar]
  7. Zhang M. Zhu X. Wu J. Huang Z. Zhao Z. Zhang X. Xue Y. Wan W. Li C. Zhang W. Wang L. Zhou M. Zou H. Wang L. Prevalence of hyperuricemia among chinese adults: Findings from two nationally representative cross-sectional surveys in 2015–16 and 2018–19. Front. Immunol. 2022 12 791983 10.3389/fimmu.2021.791983 35197964
    [Google Scholar]
  8. Li L. Zhang Y. Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am. J. Transl. Res. 2020 12 7 3167 3181 [PMID: 32774692
    [Google Scholar]
  9. Mohammad C.M. Che Alhadi S. Wan Fatimah S.W.M. Salman A. Mohd Zhafri M.R. Rasimah I. Delayed hypersensitivity reaction to allopurinol: A case report. Malays. Fam. Physician 2023 18 11 10.51866/cr.65 36992954
    [Google Scholar]
  10. Yuan J.S.J. Shashidhara A. Sutaria A. Tahir S.H. Tahir H. An update on the pharmacotherapy of gout. Expert Opin. Pharmacother. 2025 26 1 101 109 10.1080/14656566.2024.2442028 39665289
    [Google Scholar]
  11. Liu P. Xu Y. Ye J. Tan J. Hou J. Wang Y. Li J. Cui W. Wang S. Zhao Q. Qingre Huazhuo Jiangsuan Decoction promotes autophagy by inhibiting PI3K/AKT/mTOR signaling pathway to relieve acute gouty arthritis. J. Ethnopharmacol 2023 32 (Part A) 115875 10.1016/j.jep.2022.115875
    [Google Scholar]
  12. Shang Y. Dong X. Xie Z. Li X. Wang X. Huang J. Wei S. Liu Y. Liu J. Efficacy and safety of Tibetan medicine Qingpeng ointment for acute gouty arthritis: Protocol for a multi-center, randomized, double-blind, placebo-controlled trial. Trials 2022 23 1 387 10.1186/s13063‑022‑06338‑1 35549757
    [Google Scholar]
  13. Guo J. Lin G. Tang X. Yao J. Feng C. Zuo J. He S. Therapeutic potential and pharmacological mechanisms of Traditional Chinese Medicine in gout treatment. Acta Pharmacol. Sin. 2025 10.1038/s41401‑024‑01459‑6 39825190
    [Google Scholar]
  14. Li H. Yuan Q. Sun W. Shao Z. Huang X. Hu L. Zhang X. Investigating the mechanism of Tongfeng Qingxiao Formula for improving gouty arthritis based on the neutrophil extracellular trapping network. J. Ethnopharmacol. 2025 341 119304 10.1016/j.jep.2024.119304 39736350
    [Google Scholar]
  15. Wang Y.B. Jin C.Z. Roles of traditional Chinese medicine extracts in hyperuricemia and gout treatment: Mechanisms and clinical applications. World J. Gastroenterol. 2024 30 47 5076 5080 10.3748/wjg.v30.i47.5076 39713159
    [Google Scholar]
  16. Liao X.Z. Xie R.X. Zheng S.Y. Fan C.L. Zuo M.Y. Chen S.X. Zhu J.Q. Li J. Bioinformatics and molecular docking reveal Cryptotanshinone as the active anti-inflammation component of Qu-Shi-Xie-Zhuo decoction by inhibiting S100A8/A9-NLRP3-IL-1β signaling. Phytomedicine 2025 136 156257 10.1016/j.phymed.2024.156257 39631292
    [Google Scholar]
  17. Xiao N. Zhang X. Xi Y. Li Z. Wei Y. Shen J. Wang L. Qin D. Xie Z. Li Z. Study on the effects of intestinal flora on gouty arthritis. Front. Cell. Infect. Microbiol. 2024 14 1341953 10.3389/fcimb.2024.1341953 39176260
    [Google Scholar]
  18. Yang S. Liu H. Fang X.M. Yan F. Zhang Y. Signaling pathways in uric acid homeostasis and gout: From pathogenesis to therapeutic interventions. Int. Immunopharmacol. 2024 132 111932 10.1016/j.intimp.2024.111932 38560961
    [Google Scholar]
  19. Zhou H. Yang J. Yuan X. Song X. Zhang X. Cao T. Zhang J. Hyperuricemia research progress in model construction and traditional Chinese medicine interventions. Front. Pharmacol. 2024 15 1294755 10.3389/fphar.2024.1294755 38515855
    [Google Scholar]
  20. Zhou B. Li W. Luo Z. Zhu L. Yu J. Guo Y. Li W. Xiong H. Lu X. Therapeutic effects and mechanisms of Juanbilijieqing fang in ameliorating gouty arthritis in a murine model. Toxicol. Res. 2024 14 1 tfaf005 10.1093/toxres/tfaf005 39830888
    [Google Scholar]
  21. Zeng D. Yin C. Wei H. Li Y. Yang Y. Nie H. Pan Y. Xu R. Tai Y. Du J. Liu J. Wang P. Liu B. Liu B. Activation of Nrf2 antioxidant signaling alleviates gout arthritis pain and inflammation. Biomed. Pharmacother. 2024 170 115957 10.1016/j.biopha.2023.115957
    [Google Scholar]
  22. Ni X. Wang Q. Ning Y. Liu J. Su Q. Lv S. Feng Y. Yang S. Yuan R. Gao H. Anemoside B4 targets NEK7 to inhibit NLRP3 inflammasome activation and alleviate MSU-induced acute gouty arthritis by modulating the NF-κB signaling pathway. Phytomedicine 2025 138 156407 10.1016/j.phymed.2025.156407 39939033
    [Google Scholar]
  23. Shi M.F. Liu X. Ma X.N. Feng W. Zhang Y.F. Lin C.S. Liu Q.P. Xu Q. Study on the effect and mechanism of ZeXie decoction in treating MSU-induced acute gouty arthritis model through PI3K-AKT-mTOR signaling pathway. Int. Immunopharmacol. 2025 150 114214 10.1016/j.intimp.2025.114214 39952005
    [Google Scholar]
  24. Liu Z.Q. Sun X. Liu Z.B. Zhang T. Zhang L.L. Wu C.J. Phytochemicals in traditional Chinese medicine can treat gout by regulating intestinal flora through inactivating NLRP3 and inhibiting XOD activity. J. Pharm. Pharmacol. 2022 74 7 919 929 10.1093/jpp/rgac024 35640306
    [Google Scholar]
  25. Dang W. Xu D. Zhou J. Effect of berberine on activation of TLR4-NFκB signaling pathway and NLRP3 inflammasome in patients with gout. Chin. J. Integr. Med. 2023 29 1 10 18 10.1007/s11655‑022‑3720‑7 36125615
    [Google Scholar]
  26. Yin X. Gao Q. Li C. Yang Q. HongliangDong; Li, Z. Leonurine alleviates vancomycin nephrotoxicity via activating PPARγ and inhibiting the TLR4/NF-κB/TNF-α pathway. Int. Immunopharmacol. 2024 131 111898 10.1016/j.intimp.2024.111898 38513573
    [Google Scholar]
  27. Wang R. Ji C.L. Feng D.D. Wu Y.J. Li Y. Olatunji O.J. Yu L.J. Zuo J. Consumption of saturated fatty acids‐rich lard benefits recovery of experimental arthritis by activating PPAR‐γ. Mol. Nutr. Food Res. 2023 67 2 2200429 10.1002/mnfr.202200429 36433679
    [Google Scholar]
  28. Guo Y. Hui X. Lu X. The replication of a modified gouty arthritis rat model. J. Yun-nan Univ. Tradit Chin Med 2 40 18 23
    [Google Scholar]
  29. Putra A.B.N. Nishi K. Shiraishi R. Doi M. Sugahara T. Jellyfish collagen stimulates production of TNF-α and IL-6 by J774.1 cells through activation of NF-κB and JNK via TLR4 signaling pathway. Mol. Immunol. 2014 58 1 32 37 10.1016/j.molimm.2013.11.003 24291243
    [Google Scholar]
  30. Wang R.C. Jiang D.M. PPAR-γ agonist pioglitazone affects rat gouty arthritis by regulating cytokines. Genet. Mol. Res. 2014 13 3 6577 6581 10.4238/2014.August.28.2 25177938
    [Google Scholar]
  31. Liu Y.F. Tu S.H. Chen Z. Wang Y. Hu Y.H. Dong H. Effects of modified simiao decoction on IL‐1 β and TNF α secretion in monocytic THP‐1 cells with monosodium urate crystals‐induced inflammation. Evid. Based Complement. Alternat. Med. 2014 2014 1 406816 10.1155/2014/406816 24999366
    [Google Scholar]
  32. Dalbeth N. Choi H.K. Joosten L.A.B. Khanna P.P. Matsuo H. Perez-Ruiz F. Stamp L.K. Gout. Nat. Rev. Dis. Primers 2019 5 1 69 10.1038/s41572‑019‑0115‑y 31558729
    [Google Scholar]
  33. Deng P. Wang S. Sun X. Qi Y. Ma Z. Pan X. Liang H. Wu J. Chen Z. Global trends in research of gouty arthritis over past decade: A bibliometric analysis. Front. Immunol. 2022 13 910400 10.3389/fimmu.2022.910400 35757713
    [Google Scholar]
  34. Dilokthornsakul P. Louthrenoo W. Chevaisrakul P. Siripaitoon B. Jatuworapruk K. Upakdee N. Buttham B. Towiwat P. Impact of gout flare on health-related quality of life: A multi-center cross-sectional study in Thailand. Clin. Rheumatol. 2025 44 3 1317 1327 10.1007/s10067‑025‑07339‑6 39888479
    [Google Scholar]
  35. Yang P. Chen Z. Chen Y.T. Liu M. Zhang M. Yang X. Lin C. Xu Q. Use of the gout impact scale to evaluate quality of life in Chinese subjects with gout: A cross-sectional study. Med. Sci. Monit. 2020 26 e925593 10.12659/MSM.925593 32991572
    [Google Scholar]
  36. Bekaryssova D. Yessirkepov M. Mahmudov K. Structure, demography, and medico-social characteristics of articular syndrome in rheumatic diseases: A retrospective monocentric analysis of 2019–2021 data. Rheumatol. Int. 2023 43 11 2057 2064 10.1007/s00296‑023‑05435‑x 37624400
    [Google Scholar]
  37. Bardin T. Voshaar M.A. van de Laar M.A. The human and economic burden of difficult-to-treat gouty arthritis. Joint Bone Spine 2015 82 Suppl. 1 eS2 eS8 10.1016/S1297‑319X(15)30003‑8 26717799
    [Google Scholar]
  38. Cao L. Zhao T. Xue Y. Xue L. Chen Y. Quan F. Xiao Y. Wan W. Han M. Jiang Q. Lu L. Zou H. Zhu X. The anti-inflammatory and uric acid lowering effects of si-miao-san on gout. Front. Immunol. 2022 12 777522 10.3389/fimmu.2021.777522 35069549
    [Google Scholar]
  39. Zhao T. Cao L. Lin C. Xu R. Du X. Zhou M. Yang X. Wan W. Zou H. Zhu X. Intestinal uric acid excretion contributes to serum uric acid decrease during acute gout attack. Rheumatology 2023 62 12 3984 3992 10.1093/rheumatology/kead139 37042723
    [Google Scholar]
  40. Timsans J. Palomäki A. Kauppi M. Gout and hyperuricemia: A narrative review of their comorbidities and clinical implications. J. Clin. Med. 2024 13 24 7616 10.3390/jcm13247616 39768539
    [Google Scholar]
  41. Chenchula S. Ghanta M.K. Alhammadi M. Mohammed A. Anitha K. Nuthalapati P. Raju G.S.R. Huh Y.S. Bhaskar L.V.K.S. Phytochemical compounds for treating hyperuricemia associated with gout: A systematic review. Naunyn Schmiedebergs Arch. Pharmacol. 2024 398 5 4779 4801 10.1007/s00210‑024‑03686‑4 39636406
    [Google Scholar]
  42. Yanai H. Adachi H. Hakoshima M. Katsuyama H. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int. J. Mol. Sci. 2021 22 17 9221 10.3390/ijms22179221 34502127
    [Google Scholar]
  43. Cabău G. Crișan T.O. Klück V. Popp R.A. Joosten L.A.B. Urate‐induced immune programming: Consequences for gouty arthritis and hyperuricemia. Immunol. Rev. 2020 294 1 92 105 10.1111/imr.12833 31853991
    [Google Scholar]
  44. Li D. Yuan S. Deng Y. Wang X. Wu S. Chen X. Li Y. Ouyang J. Lin D. Quan H. Fu X. Li C. Mao W. The dysregulation of immune cells induced by uric acid: mechanisms of inflammation associated with hyperuricemia and its complications. Front. Immunol. 2023 14 1282890 10.3389/fimmu.2023.1282890 38053999
    [Google Scholar]
  45. Quintana M.J. Shum A.Z. Folse M.S. Ramesh P.C. Ahmadzadeh S. Varrassi G. Shekoohi S. Kaye A.D. Gout treatment and clinical considerations: The role of pegloticase, colchicine, and febuxostat. Cureus 2023 15 10 e46649 10.7759/cureus.46649 37937020
    [Google Scholar]
  46. Huang X. Zhu Z. Wu G. Min P. Fei P. Zhu T. Huang X. Wang X. Xiao L. Efficacy and safety of external application of Traditional Chinese Medicine for the treatment of acute gouty arthritis: A systematic review and Meta-analysis. J. Tradit. Chin. Med. 2019 39 3 297 306 [PMID: 32186001
    [Google Scholar]
  47. Wang H.R. Fu Q. Liu Z. Li M.L. Zhai S.Q. A systematic review and meta‐analysis of randomized controlled trials: Skin‐patch of Chinese herbal medicine for patients with acute gouty arthritis. J. Adv. Nurs. 2018 74 8 1769 1786 10.1111/jan.13571 29574941
    [Google Scholar]
  48. Wang H. Chen S. Ding X. Kuai L. Hua L. Li X. Wang Y. Zhang M. Li B. Wang R. Zhou M. Efficacy and safety of Huzhang Granule, a compound Chinese herbal medicine, for acute gouty arthritis: A double-blind, randomized controlled trial. J. Integr. Med. 2024 22 3 270 278 10.1016/j.joim.2024.03.008 38553375
    [Google Scholar]
  49. Wang S. Liu W. Wei B. Wang A. Wang Y. Wang W. Gao J. Jin Y. Lu H. Ka Y. Yue Q. Traditional herbal medicine: Therapeutic potential in acute gouty arthritis. J. Ethnopharmacol. 2024 330 118182 10.1016/j.jep.2024.118182 38621464
    [Google Scholar]
  50. Fan W. Chen S. Wu X. Zhu J. Li J. Resveratrol relieves gouty arthritis by promoting mitophagy to inhibit activation of NLRP3 inflammasomes. J. Inflamm. Res. 2021 14 3523 3536 10.2147/JIR.S320912 34335041
    [Google Scholar]
  51. Peng S. Tian J. Jin L. Wang H. Xie C. Zheng J. Liu L. Cao J. Zhang W. Zhang X. Efficacy and safety of Danggui Niantong Decoction in patients with gout: A systematic review and meta-analysis. Front. Pharmacol. 2023 14 1168863 10.3389/fphar.2023.1168863 37587984
    [Google Scholar]
  52. Lin X. Wang M. He Z. Hao G. Correction: Gut microbiota mediated the therapeutic efficiency of Simiao decoction in the treatment of gout arthritis mice. BMC Complement Med. Ther. 2023 23 1 245 10.1186/s12906‑023‑04090‑w 37460996
    [Google Scholar]
  53. Wang H. Chu Z. Ni T. Chen D. Dai X. Jiang W. Sunagawa M. Liu Y. Effect and mechanism of aqueous extract of Chinese herbal prescription (TFK) in treating gout arthritis. J. Ethnopharmacol. 2024 321 117527 10.1016/j.jep.2023.117527 38056535
    [Google Scholar]
  54. Yuan W. Liu T. Wang Y. He S. Zhang F. Wang X. Deng S. Zhang T. Wu D. Xu Y. Autophagy induced by PP121 alleviates MSU crystal-induced acute gouty arthritis via inhibition of the NLRP3 inflammasome. Int. Immunopharmacol. 2023 123 110756 10.1016/j.intimp.2023.110756 37573689
    [Google Scholar]
  55. Sui X. Xie T. Xu Y. Zhang A. Zhang Y. Gu F. Li L. Xu Z. Chen J. Protease-activated receptor-2 and phospholipid metabolism analysis in hyperuricemia-induced renal injury. Mediators Inflamm. 2023 2023 1 15 10.1155/2023/5007488 37484603
    [Google Scholar]
  56. Wu M. Ma Y. Chen X. Liang N. Qu S. Chen H. Hyperuricemia causes kidney damage by promoting autophagy and NLRP3-mediated inflammation in rats with urate oxidase deficiency. Dis. Model. Mech. 2021 14 3 dmm048041 10.1242/dmm.048041 33648977
    [Google Scholar]
  57. Dalbeth N. Merriman T.R. Stamp L.K. Gout. Lancet 2016 388 10055 2039 2052 10.1016/S0140‑6736(16)00346‑9 27112094
    [Google Scholar]
  58. So A.K. Martinon F. Inflammation in gout: Mechanisms and therapeutic targets. Nat. Rev. Rheumatol. 2017 13 11 639 647 10.1038/nrrheum.2017.155 28959043
    [Google Scholar]
  59. Schlee S. Bollheimer L.C. Bertsch T. Sieber C.C. Härle P. Crystal arthritides – Gout and calcium pyrophosphate arthritis. Z. Gerontol. Geriatr. 2018 51 4 453 460 10.1007/s00391‑017‑1197‑3 28233117
    [Google Scholar]
  60. Zhang Q.B. Zhu D. Dai F. Huang Y.Q. Zheng J.X. Tang Y.P. Dong Z.R. Liao X. Qing Y.F. MicroRNA-223 suppresses IL-1β and TNF-α production in gouty inflammation by targeting the NLRP3 inflammasome. Front. Pharmacol. 2021 12 637415 10.3389/fphar.2021.637415 33935726
    [Google Scholar]
  61. Amaral F.A. Bastos L.F.S. Oliveira T.H.C. Dias A.C.F. Oliveira V.L.S. Tavares L.D. Costa V.V. Galvão I. Soriani F.M. Szymkowski D.E. Ryffel B. Souza D.G. Teixeira M.M. Transmembrane TNF‐α is sufficient for articular inflammation and hypernociception in a mouse model of gout. Eur. J. Immunol. 2016 46 1 204 211 10.1002/eji.201545798 26449770
    [Google Scholar]
  62. So A. Dumusc A. Nasi S. The role of IL-1 in gout: From bench to bedside. Rheumatology 2018 57 Suppl. 1 i12 i19 [PMID: 29272514
    [Google Scholar]
  63. Renaudin F. Orliaguet L. Castelli F. Fenaille F. Prignon A. Alzaid F. Combes C. Delvaux A. Adimy Y. Cohen-Solal M. Richette P. Bardin T. Riveline J.P. Venteclef N. Lioté F. Campillo-Gimenez L. Ea H.K. Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1β activation on macrophages. Ann. Rheum. Dis. 2020 79 11 1506 1514 10.1136/annrheumdis‑2020‑217342 32699039
    [Google Scholar]
  64. Schlesinger N. Pillinger M.H. Simon L.S. Lipsky P.E. Interleukin-1β inhibitors for the management of acute gout flares: A systematic literature review. Arthritis Res. Ther. 2023 25 1 128 10.1186/s13075‑023‑03098‑4 37491293
    [Google Scholar]
  65. Cavalcanti N.G. Marques C.D.L. Lins e Lins T.U. Pereira M.C. Rêgo M.J.B.M. Duarte A.L.B.P. Pitta I.R. Pitta M.G.R. Cytokine profile in gout: Inflammation driven by IL-6 and IL-18? Immunol. Invest. 2016 45 5 383 395 10.3109/08820139.2016.1153651 27219123
    [Google Scholar]
  66. Zhang Z. Wang P. Xiong Q. Xu S. Kang D. He Z. Yao C. Jian G. Advancements in the study of IL-6 and its receptors in the pathogenesis of gout. Cytokine 2024 182 156705 10.1016/j.cyto.2024.156705 39053079
    [Google Scholar]
  67. Ea H.K. Kischkel B. Chirayath T.W. Klück V. Aparicio C. Loeung H.U. Manivet P. Jansen T. Zarka M. Lioté F. Latourte A. Bardin T. Gauffenic A. Vicaut E. Crișan T.O. Netea M.G. Richette P. Joosten L. Systemic inflammatory cytokine profiles in patients with gout during flare, intercritical and treat-to-target phases: TNFSF14 as new biomarker. Ann. Rheum. Dis. 2024 83 7 1 12 10.1136/ard‑2023‑225305 38373842
    [Google Scholar]
  68. Martinon F. Pétrilli V. Mayor A. Tardivel A. Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006 440 7081 237 241 10.1038/nature04516 16407889
    [Google Scholar]
  69. Silva C.R. Saraiva A.L. Rossato M.F. Trevisan G. Oliveira S.M. What do we know about toll-like receptors involvement in gout arthritis? Endocr. Metab. Immune Disord. Drug Targets 2023 23 4 446 457 10.2174/1871530322666220523145728 35616672
    [Google Scholar]
  70. Joosten L.A.B. Abdollahi-Roodsaz S. Dinarello C.A. O’Neill L. Netea M.G. Toll-like receptors and chronic inflammation in rheumatic diseases: New developments. Nat. Rev. Rheumatol. 2016 12 6 344 357 10.1038/nrrheum.2016.61 27170508
    [Google Scholar]
  71. Gu W. Zhao J. Xu Y. Hyperuricemia-induced complications: Dysfunctional macrophages serve as a potential bridge. Front. Immunol. 2025 16 1512093 10.3389/fimmu.2025.1512093 39935474
    [Google Scholar]
  72. Liu-Bryan R. Scott P. Sydlaske A. Rose D.M. Terkeltaub R. Innate immunity conferred by toll‐like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal–induced inflammation. Arthritis Rheum. 2005 52 9 2936 2946 10.1002/art.21238 16142712
    [Google Scholar]
  73. Liu-Bryan R. Pritzker K. Firestein G.S. Terkeltaub R. TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J. Immunol. 2005 174 8 5016 5023 10.4049/jimmunol.174.8.5016
    [Google Scholar]
  74. Wang N. Kong R. Han W. Bao W. Shi Y. Ye L. Lu J. Honokiol alleviates ulcerative colitis by targeting PPAR-γ–TLR4–NF-κB signaling and suppressing gasdermin-D-mediated pyroptosis in vivo and in vitro. Int. Immunopharmacol. 2022 111 109058 10.1016/j.intimp.2022.109058 35901530
    [Google Scholar]
  75. Hu X. Qin H. Li Y. Li J. Fu L. Li M. Jiang C. Yun J. Liu Z. Feng Y. Yao Y. Yin B. Biochanin A protect against lipopolysaccharide-induced acute lung injury in mice by regulating TLR4/NF-κB and PPAR-γ pathway. Microb. Pathog. 2020 138 103846 10.1016/j.micpath.2019.103846 31698051
    [Google Scholar]
  76. Morsy M.A. Abdel-Gaber S.A. Rifaai R.A. Mohammed M.M. Nair A.B. Abdelzaher W.Y. Protective mechanisms of telmisartan against hepatic ischemia/reperfusion injury in rats may involve PPARγ-induced TLR4/NF-κB suppression. Biomed. Pharmacother. 2022 145 112374 10.1016/j.biopha.2021.112374
    [Google Scholar]
/content/journals/cchts/10.2174/0113862073378606250616114958
Loading
Juanbi Lijieqing Decoction Inhibits TLR4/NF-κB Signaling Pathway by Promoting PPARγ Expression to Relieve Acute Gouty Arthritis
Bentham Science Publishers ; https://doi.org/10.2174/0113862073378606250616114958
/content/journals/cchts/10.2174/0113862073378606250616114958
/content/journals/cchts/10.2174/0113862073378606250616114958
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: TLR4 ; PPARγ ; chinese medicine ; NF-κB ; acute gouty arthritis ; Juanbi Lijieqing Decoction ; uric acid

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test